Literature DB >> 8003563

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

S Rupoli1, L Da Lio, S Sisti, G Campanati, A Salvi, M F Brianzoni, S D'Amico, A Cinciripini, P Leoni.   

Abstract

In the present study we analyzed the prognostic significance of several clinical, hematological, and histological parameters recorded at diagnosis in a consecutive series of 72 patients with primary myelofibrosis (PMF). Univariate analysis showed that the most significant indicators of poor survival were the following: age greater than 60, splenomegaly, anemia (hemoglobin > 10 g/dl), leukopenia (WBC < 4 x 10(9)/l or leukocytosis > 14 x 10(9)/l), and any of these histological features: adipose tissue and megakaryocyte reduction, prominent osteoblastic rims along the trabecular bone, presence of peritrabecular megakaryocytes (Mk), absence of normal or giant Mk. The multivariate analysis showed that only the level of hemoglobin and the presence of both normal Mk and fever independently influenced the prognosis. These parameters were used to set up a prognostic scoring system, allowing a feasible prognosis to be made for each patient at the time of diagnosis and identifying those patients in urgent need of new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8003563     DOI: 10.1007/BF01834368

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  28 in total

1.  Myelofibrosis. Clinical, hematologic and pathologic study of 110 patients.

Authors:  B A BOURONCLE; C A DOAN
Journal:  Am J Med Sci       Date:  1962-06       Impact factor: 2.378

2.  Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation.

Authors:  A Pereira; F Cervantes; R Brugues; C Rozman
Journal:  Eur J Haematol       Date:  1990-02       Impact factor: 2.997

3.  Myeloid metaplasia: a study of 98 cases.

Authors:  D S Rosenthal; W C Moloney
Journal:  Postgrad Med       Date:  1969-03       Impact factor: 3.840

4.  Anaemia in myelofibrosis: its value in prognosis.

Authors:  O S Njoku; S M Lewis; D Catovsky; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

Review 5.  The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.

Authors:  H P Ward; M H Block
Journal:  Medicine (Baltimore)       Date:  1971-09       Impact factor: 1.889

6.  [Prognostic value of bone and bone marrow lesions of primary myeloid metaplasia].

Authors:  N Chelloul; C Jacquillat; J Brière; M Laval-Jeantet; W Vorhauer-Atlan
Journal:  Nouv Presse Med       Date:  1975-12-13

Review 7.  Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components.

Authors:  H Castro-Malaspina
Journal:  Prog Clin Biol Res       Date:  1984

8.  Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases.

Authors:  J L Demory; B Dupriez; P Fenaux; J L Laï; R Beuscart; J P Jouet; M Deminatti; F Bauters
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

9.  Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.

Authors:  G Visani; C Finelli; U Castelli; M C Petti; P Ricci; N Vianelli; L Gianni; E Zuffa; M A Aloe Spiriti; R Latagliata
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

Review 10.  Chronic myeloproliferative disorders (CMPD).

Authors:  R Burkhardt; R Bartl; K Jäger; B Frisch; G Kettner; G Mahl; M Sund
Journal:  Pathol Res Pract       Date:  1984-11       Impact factor: 3.250

View more
  4 in total

Review 1.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

Review 3.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Gianluca Viarengo; Laura Villani; Umberto Magrini
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.